Information Provided By: 
Fly News Breaks for November 11, 2019
EYPT
Nov 11, 2019 | 07:15 EDT
H.C. Wainwright analyst Yi Chen downgraded EyePoint Pharmaceuticals to Neutral from Buy without a price target. Though the growth in demand for Dexycu and Yutiq "has been generally satisfying," quarterly product revenue could continue to fluctuate based on the timing of distributor orders, Chen tells investors in a post-earnings research note. This is concerning, since EyePoint's term loan agreement with CRG contains the covenant that requires the company to deliver minimum product revenue of $15M during 2019, says the analyst.
News For EYPT From the Last 2 Days
EYPT
Apr 29, 2024 | 15:10 EDT
Welcome to "Fly Insider," The Fly's weekly recap of notable insider stock transactions. NOTABLE INSIDER PURCHASES:... To see the rest of the story go to thefly.com. See Story Here
